Effect of one-month treatment with vaginal promestriene on serum estrone sulfate levels in cancer patients: A pilot study

L. Del Pup, D. Postruznik, G. Corona

Research output: Contribution to journalArticlepeer-review

Abstract

Vaginal promestriene was tested in gynecological cancer patients who suffered from severe vaginal dryness and dyspareunia. This form of estrogen has a low level of vaginal absorption and proved to be effective for vaginal atrophy. Method: 17 patients were treated with a 10 mg soft vaginal suppository daily for one month. Plasma levels of estrone sulfate (E1S), used as the marker of overall estrogenicity, were measured by liquid chromatography in combination with mass spectrometry. Results: Mean E1S levels changed from 533 (22-2920) to 374 (81-856) pg/ml (p = 0.39). Conclusion: In highly symptomatic gynecological cancer patients the level of circulating estrone sulfate was not significantly affected by vaginal promestriene treatment overall, but a wide range of levels was noted pre and post treatment in individual patients.

Original languageEnglish
Pages (from-to)93-94
Number of pages2
JournalMaturitas
Volume72
Issue number1
DOIs
Publication statusPublished - May 2012

Keywords

  • Dyspareunia
  • Estrone sulphate
  • Female cancer patients
  • Promestriene
  • Vaginal dryness
  • Vaginal estrogens

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Effect of one-month treatment with vaginal promestriene on serum estrone sulfate levels in cancer patients: A pilot study'. Together they form a unique fingerprint.

Cite this